ReviewProteomics. Clinical applications2010
Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective.
Review in Proteomics. Clinical applications, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Beyond hyperglycaemia: diabetic retinopathy is a multifactorial complication of diabetes mellitus.Annals of medicine · 2026Review
- An Inflection Point in Cancer Protein Biomarkers: What was and What's Next.Molecular & cellular proteomics : MCP · 2023Article
- Clinical potential of mass spectrometry-based proteogenomics.Nature reviews. Clinical oncology · 2019Review
- Serum biomarkers identification by iTRAQ and verification by MRM: S100A8/S100A9 levels predict tumor-stroma involvement and prognosis in Glioblastoma.Scientific reports · 2019Article
- Article
- Multiplexed Targeted Mass Spectrometry-Based Assays for the Quantification of N-Linked Glycosite-Containing Peptides in Serum.Analytical chemistry · 2015Article
- Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays.Molecular oncology · 2014Review
- Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins.Nature methods · 2014Article
- Advances in Proteomic Technologies and Its Contribution to the Field of Cancer.Advances in medicine · 2014Review
- Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies.Journal of proteome research · 2013Article
- Clinical review: improving the measurement of serum thyroglobulin with mass spectrometry.The Journal of clinical endocrinology and metabolism · 2013Review
- Proteomic classification of acute leukemias by alignment-based quantitation of LC-MS/MS data sets.Journal of proteome research · 2012Article
- Cardiac myosin binding protein-C: a potential early-stage, cardiac-specific biomarker of ischemia-reperfusion injury.Biomarkers in medicine · 2012Article
- Article
- 18O-labeled proteome reference as global internal standards for targeted quantification by selected reaction monitoring-mass spectrometry.Molecular & cellular proteomics : MCP · 2011Article
- A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples.Journal of translational medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Proteomics holds great promise in personalized medicine for cancer in the post-genomic era. In the past decade, clinical proteomics has significantly evolved in terms of technology development, optimization and standardization, as well as in advanced bioinformatics data integration and analysis. Great strides have been made for characterizing a large number of proteins qualitatively and quantitatively in a proteome, including the use of sample fractionation, protein microarrays and MS. It is believed that differential proteomic analysis of high-quality clinical biospecimen (tissue and biofluids) can potentially reveal protein/peptide biomarkers responsible for cancer by means of their altered levels of expression and/or PTMs. Multiple reaction monitoring, a multiplexed platform using stable isotope dilution-MS with sensitivity and reproducibility approaching that of traditional ELISAs commonly used in the clinical setting, has emerged as a potentially promising technique for next-generation high-throughput protein biomarker measurements for diagnostics and therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.